Human blood plasma as source for biotherapeutics is very limited and safety concerns still persist, leading to a growing need for recombinant Plasma Proteins. In addition, glycosylation patterns of most Plasma Proteins are very complex and represent a huge challenge to recombinant protein expression. With a comprehensive portfolio of glyco-optimized human cell lines, the CAP®Go expression system paves the way for recombinant Plasma Proteins.
Recombinant human C1 Inhibitor (C1-INH)
C1-Inhibitor deficiency patients suffer from an inherited form of angioedema which is currently predominantly being treated with intravenous injections of C1 Inhibitor purified from human serum. CEVEC´s CAP®Go derived C1 Inhibitor showed in a pivotal pharmacokinetic rat study a serum half-life matching Berinert®, one of the two currently available, plasma derived treatments. This result, in combination with excellent specific activities of CAP®Go derived C1 Inh and commercially attractive production yields, paves the way to develop a safer and more economic therapy for acute and prophylactic HAE indications.
CAP®Go derived human C1 Inh matches PK of plasma purified C1 Inh Berinert
A Specific inhibitory activity of rhC1 inhibitor produced in CAP®Go.2 was compared with a commercially available preparation of serum C1 Inh (Berinert).
B Residual C1 Inh was measured in the serum of rats injected with conventional recombinant hC1 Inh, rhC1 Inh produced in CAP®Go.2 cells or Berinert.
C Serum half life of conventional recombinant hC1 Inh and C1 Inh produced in different CAP®Go cell lines in comparison to Berinert.